Trial Profile
Effect of the long acting ARB in hypertensive patients with cerebro vasucular disease not controlled by conventional therapy.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Angiotensin receptor antagonists
- Indications Essential hypertension
- Focus Therapeutic Use
- 31 Jan 2013 New trial record